Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.
Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L, Lalloo U, Masilela MSL, Moodley D, Hanley S, Fouche L, Louw C, Tameris M, Singh N, Goga A, Dheda K, Grobbelaar C, Kruger G, Carrim-Ganey N, Baillie V, de Oliveira T, Lombard Koen A, Lombaard JJ, Mngqibisa R, Bhorat AE, Benadé G, Lalloo N, Pitsi A, Vollgraaff PL, Luabeya A, Esmail A, Petrick FG, Oommen-Jose A, Foulkes S, Ahmed K, Thombrayil A, Fries L, Cloney-Clark S, Zhu M, Bennett C, Albert G, Faust E, Plested JS, Robertson A, Neal S, Cho I, Glenn GM, Dubovsky F, Madhi SA; 2019nCoV-501 Study Group. Shinde V, et al. Among authors: plested js. N Engl J Med. 2021 May 20;384(20):1899-1909. doi: 10.1056/NEJMoa2103055. Epub 2021 May 5. N Engl J Med. 2021. PMID: 33951374 Free PMC article. Clinical Trial.
Safety, Immunogenicity and Efficacy of NVX-CoV2373 in Adolescents in PREVENT-19: A Randomized, Phase 3 Trial.
Áñez G, Dunkle LM, Gay CL, Kotloff KL, Adelglass JM, Essink B, Campbell JD, Cloney-Clark S, Zhu M, Plested JS, Roychoudhury P, Greninger AL, Patel N, McGarry A, Woo W, Cho I, Glenn GM, Dubovsky F; 2019nCoV-301 – Pediatric Expansion Study Group. Áñez G, et al. Among authors: plested js. medRxiv [Preprint]. 2022 Sep 21:2022.09.20.22279903. doi: 10.1101/2022.09.20.22279903. medRxiv. 2022. PMID: 36172135 Free PMC article. Preprint.
Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373.
Alves K, Plested JS, Galbiati S, Chau G, Cloney-Clark S, Zhu M, Kalkeri R, Patel N, Smith K, Marcheschi A, Pfeiffer S, McFall H, Smith G, Glenn GM, Dubovsky F, Mallory RM; Novavax 2019nCoV-101 Study Group. Alves K, et al. Among authors: plested js. N Engl J Med. 2023 Mar 2;388(9):857-859. doi: 10.1056/NEJMc2215509. Epub 2023 Jan 25. N Engl J Med. 2023. PMID: 36734884 Free PMC article. No abstract available.
Severe Acute Respiratory Syndrome Coronavirus 2 Receptor (Human Angiotensin-Converting Enzyme 2) Binding Inhibition Assay: A Rapid, High-Throughput Assay Useful for Vaccine Immunogenicity Evaluation.
Plested JS, Zhu M, Cloney-Clark S, Massuda E, Patel U, Klindworth A, Massare MJ, Cai R, Fries L, Glenn G, Kalkeri R. Plested JS, et al. Microorganisms. 2023 Feb 1;11(2):368. doi: 10.3390/microorganisms11020368. Microorganisms. 2023. PMID: 36838333 Free PMC article.
Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical Trial.
Áñez G, Dunkle LM, Gay CL, Kotloff KL, Adelglass JM, Essink B, Campbell JD, Cloney-Clark S, Zhu M, Plested JS, Roychoudhury P, Greninger AL, Patel N, McGarry A, Woo W, Cho I, Glenn GM, Dubovsky F; 2019nCoV-301–Pediatric Expansion Study Group. Áñez G, et al. Among authors: plested js. JAMA Netw Open. 2023 Apr 3;6(4):e239135. doi: 10.1001/jamanetworkopen.2023.9135. JAMA Netw Open. 2023. PMID: 37099299 Free PMC article. Clinical Trial.
Strong CD4+ T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 Severe Acute Respiratory Syndrome Coronavirus 2 Primary Vaccination.
Fries L, Formica N, Mallory RM, Zhou H, Plested JS, Kalkeri R, Moldovan I, Patel N, Albert G, Robinson M, Cho I, Chau G, Dubovsky F, Glenn GM; 2019nCoV-101 Study Group. Fries L, et al. Among authors: plested js. J Infect Dis. 2023 Sep 15;228(6):734-741. doi: 10.1093/infdis/jiad163. J Infect Dis. 2023. PMID: 37210741 Free PMC article. Clinical Trial.
Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373.
Alves K, Plested JS, Galbiati S, Chau G, Cloney-Clark S, Zhu M, Kalkeri R, Patel N, Smith K, Marcheschi A, Pfeiffer S, McFall H, Smith G, Glenn GM, Dubovsky F, Mallory RM; Novavax 2019nCoV-101 Study Group. Alves K, et al. Among authors: plested js. Vaccine. 2023 Jun 29;41(29):4280-4286. doi: 10.1016/j.vaccine.2023.05.051. Epub 2023 Jun 2. Vaccine. 2023. PMID: 37271706 Free PMC article. Clinical Trial.
A Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Immunoglobulin G Assay: A Robust Method for Evaluation of Vaccine Immunogenicity Using an Established Correlate of Protection.
Zhu M, Cloney-Clark S, Feng SL, Parekh A, Gorinson D, Silva D, Skonieczny P, Wilson A, Kalkeri R, Woo W, Cai MR, Fries L, Glenn G, Plested JS. Zhu M, et al. Among authors: plested js. Microorganisms. 2023 Jul 11;11(7):1789. doi: 10.3390/microorganisms11071789. Microorganisms. 2023. PMID: 37512961 Free PMC article.
41 results